Clinical Research Papers:
A 3-year observation of testosterone deficiency in Chinese patients with chronic heart failure
Metrics: PDF 950 views | HTML 2056 views | ?
Ying Han1,*, Weiju Sun2,*, Guizhi Sun1, Xiaolu Hou1, Zhaowei Gong1, Jing Xu1, Xiuping Bai1 and Lu Fu2
1Cardiovascular Department, The Fourth Affiliated Hospital of Harbin Medical University, Harbin 150001, China
2Cardiovascular Department, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China
*These authors contributed equally to this work and should be considered co-first authors
Lu Fu, email: [email protected]
Xiuping Bai, email: [email protected]
Keywords: testosterone deficiency, chronic heart failure, mortality, readmission
Received: April 26, 2017 Accepted: July 12, 2017 Published: August 02, 2017
Testosterone deficiency is present in a certain proportion men with chronic heart failure (CHF). Low testosterone levels in American and European patients with CHF lead to the high mortality and readmission rates. Interestingly, this relationship has not been studied in Chinese patients. To this end, 167 Chinese men with CHF underwent clinical and laboratory evaluations associated with determinations of testosterone levels. Total testosterone (TT) levels and sex hormone-binding globulin were measured by chemiluminescence or immunoassays assays and free testosterone (FT) levels were calculated, Based upon results from these assays, patients were divided into either a low testosterone (LT; n = 93) or normal testosterone (NT; n = 74) group. Subsequently, records from each patient were reviewed over a follow-up duration of at least 3 years. Patients in the LT group experienced worse cardiac function and a higher prevalence of etiology (ischemic vs. no ischemic) and comorbidity (both P < 0.05). In addition, readmission rates of patients in the LT group were higher than that of patients in the NT group (3.32 ± 1.66 VS 1.57 ± 0.89). Overall, deficiencies in FT levels were accompanied with increased mortalities (HR = 6.301, 95% CI 3.187–12.459, P < .0001).
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.